Skip to content
Screener

Pre-Tax Income at other companies

IAR
Integra LifeSciencesIART
$4.74M+101%
MiMedx Group logo
MiMedx GroupMDXG
-$17.78M-237%
SANUWAVE Health, Inc. logo
SANUWAVE Health, Inc.SNWV
$2.97M+136%
Solventum logo
SolventumSOLV
$108M+4.9%
InfuSystem Holdings logo
InfuSystem HoldingsINFU
$1.42M+460%
AngioDynamics logo
AngioDynamicsANGO
-$11.04M-80.6%

Other financials

Income statement

See full
Revenue$43.8M-56.7%
Gross profit$63.0M-22.5%
Operating income-$51.0M-305%
Net income-$96.3M-925%
EPS (diluted)-$0.77-670%

Balance sheet

See full
Cash & equivalents$46.1M-36.9%
Total debt$36.6M+19.2%
Total equity$148.3M-36.4%
Total assets$406.4M-11.9%

Cash flow

See full
Operating cash flow-$31.7M+3.7%
CapEx$1.1M-69.8%
Free cash flow-$32.8M+10.3%

Valuation

See full
Market cap$239.33M-59.1%
Enterprise value$229.8M-57.7%
P/S0.5×-0.8×

Profitability

See full
Gross margin75.9%+0.8pp
Operating margin-7.8%
Net margin-18.4%-20.8pp
FCF margin6.9%

Returns & leverage

See full
Return on equity-44.1%-48.0pp
Debt / equity0.2×+0.1×
Current ratio3.5×-0.4×

Where this comes from

Reported directly by Organogenesis Holdings Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The source filing: Organogenesis Holdings Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:15 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-338049
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Interest income, net1386695181,630
Other income (expense), net(26)731275
Total other income, net1127425301,705
Net loss before income taxes(50,880)(11,834)(119,353)(37,617)
Income tax benefit (expense)(45,387)2,442(30,070)9,382
Net loss and comprehensive loss(96,267)(9,392)(149,423)(28,235)
Accretion of redeemable convertible preferred stock to redemption value(170)(129)(329)(250)
Cumulative dividend on redeemable convertible preferred stock(2,902)(2,681)(5,746)(5,308)

Item 1. Unaudited Condensed Consolidated Financial Statements.

FAQ

What is Organogenesis Holdings Inc.'s pre-tax income?
Organogenesis Holdings Inc. (ORGO) reported pre-tax income of -$50.88M in Q2 2026.
How has Organogenesis Holdings Inc.'s pre-tax income changed year-over-year?
Organogenesis Holdings Inc.'s pre-tax income decreased by 329.9% year-over-year, from -$11.83M to -$50.88M.
What is the long-term trend for Organogenesis Holdings Inc.'s pre-tax income?
Over 2 years (2021 to 2025), Organogenesis Holdings Inc.'s pre-tax income has grown at a -13.7% compound annual growth rate (CAGR), from $63.09M to $46.97M.
What does pre-tax income mean?
Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

Ask your AI about Organogenesis Holdings Inc.'s pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude